Search research articles
Contact Us
Filters
Showing results (91-100 of 593) with videos related to
Page
of 60
Sort By:
Nature Reviews. Drug Discovery
|
December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Jenna L Riffell, Christopher J Lord, Alan Ashworth
Trends in Cancer
|
October 8, 2018
Synthetic Lethality and Cancer - Penetrance as the Major Barrier
Colm J Ryan, Ilirjana Bajrami, Christopher J Lord
BMJ (Clinical Research Ed.)
|
January 6, 2021
UK recommendations on opioid stewardship
Nicholas Levy, Linda J Lord, Dileep N Lobo
Cancer Discovery
|
November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapy
Farah L Rehman, Christopher J Lord, Alan Ashworth
Journal of Clinical Pathology
|
January 8, 2009
RNA interference screening demystified
C J Lord, S A Martin, A Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathway
Sarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology
|
October 20, 2010
Synthetic lethal approaches to breast cancer therapy
Farah L Rehman, Christopher J Lord, Alan Ashworth
European Journal of Gastroenterology & Hepatology
|
October 8, 1999
Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: an economic evaluation based on a randomized trial
M Asante, J Lord, M Mendall, et al.
American Journal of Community Psychology
|
March 23, 1999
"Nothing about me, without me": participatory action research with self-help/mutual aid organizations for psychiatric consumer/survivors
G Nelson, J Ochocka, K Griffin, et al.
Human Fertility (Cambridge, England)
|
November 24, 2001
A time for change and a time for equality--infertility services and the NHS
J Lord, L Shaw, F Dobbs, et al.
Page
of 60
Search research articles
Search
Showing results (91-100 of 593) with videos related to
Sort By:
Page
of 60
Nature Reviews. Drug Discovery
|
December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Jenna L Riffell, Christopher J Lord, Alan Ashworth
Trends in Cancer
|
October 8, 2018
Synthetic Lethality and Cancer - Penetrance as the Major Barrier
Colm J Ryan, Ilirjana Bajrami, Christopher J Lord
BMJ (Clinical Research Ed.)
|
January 6, 2021
UK recommendations on opioid stewardship
Nicholas Levy, Linda J Lord, Dileep N Lobo
Cancer Discovery
|
November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapy
Farah L Rehman, Christopher J Lord, Alan Ashworth
Journal of Clinical Pathology
|
January 8, 2009
RNA interference screening demystified
C J Lord, S A Martin, A Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathway
Sarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology
|
October 20, 2010
Synthetic lethal approaches to breast cancer therapy
Farah L Rehman, Christopher J Lord, Alan Ashworth
European Journal of Gastroenterology & Hepatology
|
October 8, 1999
Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: an economic evaluation based on a randomized trial
M Asante, J Lord, M Mendall, et al.
American Journal of Community Psychology
|
March 23, 1999
"Nothing about me, without me": participatory action research with self-help/mutual aid organizations for psychiatric consumer/survivors
G Nelson, J Ochocka, K Griffin, et al.
Human Fertility (Cambridge, England)
|
November 24, 2001
A time for change and a time for equality--infertility services and the NHS
J Lord, L Shaw, F Dobbs, et al.
Page
of 60